SLC5A2 and chronic kidney disease: Taken together, it remains unclear whether the LPD or sVLPD can slow the progression of CKD and reduce the risk of mortality, especially among those receiving the current standard medical treatment for CKD, such as RAS inhibitors and SGLT2 inhibitors.